Your browser doesn't support javascript.
Clinical and immunological impact of booster immunization with recombinant mRNA vaccines for SARS-CoV-2 in patients with pemphigus and bullous pemphigoid.
Solimani, F; Mesas-Fernández, A; Bodner, E; Carevic-Neri, M; Hasheminasab, M; Jakovljevicova, T; Philipp, A; Nast, A; Worm, M; Hilke, F J; Meier, K; Ghoreschi, K.
  • Solimani F; Department of Dermatology, Venereology and Allergology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
  • Mesas-Fernández A; Berlin Institute of Health at Charité - Universitätsmedizin Berlin, BIH Biomedical Innovation Academy, BIH Charité Clinician Scientist Program, Berlin, Germany.
  • Bodner E; Department of Dermatology, Venereology and Allergology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
  • Carevic-Neri M; Department of Dermatology, Venereology and Allergology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
  • Hasheminasab M; Department of Dermatology, Venereology and Allergology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
  • Jakovljevicova T; Department of Dermatology, Venereology and Allergology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
  • Philipp A; Department of Dermatology, Venereology and Allergology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
  • Nast A; Department of Dermatology, Venereology and Allergology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
  • Worm M; Department of Dermatology, Venereology and Allergology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
  • Hilke FJ; Department of Dermatology, Venereology and Allergology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
  • Meier K; Department of Dermatology, Venereology and Allergology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
  • Ghoreschi K; Department of Dermatology, Venereology and Allergology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
J Eur Acad Dermatol Venereol ; 37(6): e695-e697, 2023 06.
Article in English | MEDLINE | ID: covidwho-2245355

Full text: Available Collection: International databases Database: MEDLINE Main subject: Immunization, Secondary / Pemphigoid, Bullous / Pemphigus / COVID-19 Vaccines / COVID-19 Type of study: Experimental Studies / Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: J Eur Acad Dermatol Venereol Journal subject: Dermatology / Sexually Transmitted Diseases Year: 2023 Document Type: Article Affiliation country: Jdv.18967

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Immunization, Secondary / Pemphigoid, Bullous / Pemphigus / COVID-19 Vaccines / COVID-19 Type of study: Experimental Studies / Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: J Eur Acad Dermatol Venereol Journal subject: Dermatology / Sexually Transmitted Diseases Year: 2023 Document Type: Article Affiliation country: Jdv.18967